Article

Interobserver variability of cervical smears with squamous‐cell abnormalities: A philadelphia study

Department of Pathology and Laboratory Medicine, Hahnemann University, the Department of Pathology and Laboratory Medicine, Medical College Hospitals, the Department of Pathology and Laboratory Medicine, Hospital of University of Pennsylvania, the Department of Pathology, Lankenau Hospital, Philadelphia, and the Department of Pathology, Sacred Heart Hospital, Allentown, PA, Department of Laboratories, Mercy Hospital, Janesville, WI
Diagnostic Cytopathology (Impact Factor: 1.49). 11/1994; 11(4):352 - 357. DOI: 10.1002/dc.2840110408

ABSTRACT The reproducibility of reporting squamous lesions by the Bethesda System (TBS) was evaluated by distributing 20 slides to be classified among 5 panelists considered experts in the field of cytopathology. Four cases were chosen for their classic morphology and the remainder were foreseen to produce possible discrepancies within one diagnostic category. For 7/20 (35%) cases there was unanimous agreement. Participants disagreed within one category of magnitude for seven (35%) cases. In six (30%) cases there was a range of more than one category disagreement. However, additional written comments modifying TBS diagnoses often diminished the clinical significance of these discrepancies. We conclude that despite the important role of TBS in standardization of Pap smear reports, a great degree of subjectivity exists in classifying squamous abnormalities without “classic” morphology. The lack of reproducibility should be taken into account in cytology proficiency testing. Diagn Cytopathol 1994;11:352–357. © 1994 Wiley-Liss, Inc.

1 Bookmark
 · 
93 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although it is recognized that cervical cytology is highly subjective, and that there is considerable interlaboratory variation in how slides are evaluated, little is known as to how this impacts the performance of cytology. In the ATHENA trial, liquid-based cytology specimens from 46,887 eligible women ≥21 years of age were evaluated at 4 large regional US laboratories, providing a unique opportunity to evaluate the impact of interlaboratory variations on the performance of cervical cytology. All women with abnormal cytology (atypical squamous cells of undetermined significance or higher) were referred to colposcopy, as were all high-risk human papillomavirus (hrHPV)-positive women ≥25 years of age and a random subset of those ≥25 years of age who were negative by both hrHPV testing and cytology. Sociodemographics, risk factors for cervical disease, and prevalence of cervical intraepithelial neoplasia (CIN) were similar across the laboratories. There were considerable differences among the laboratories both in overall cytological abnormal rates, ranging from 3·8% to 9·9%, and in sensitivity of cytology to detect CIN grade 2 or worse (CIN2+), from 42·0% to 73·0%. In contrast, the hrHPV positivity rate varied only from 10·9% to 13·4%, and the sensitivity of hrHPV testing from 88·2% to 90·1%. These observations suggest that hrHPV testing without cytology should be considered as the initial method for cervical cancer screening. © 2013 Wiley Periodicals, Inc.
    International Journal of Cancer 10/2013; · 6.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The French Society of Clinical Cytology is conducting a study to compare the cost-effectiveness of monolayers and human papillomavirus (HPV) testing with that of conventional Papanicolaou (Pap) smears for cervical cancer screening. The protocol of this study is presented. It includes 3,000 women who will be evaluated by the three methods (conventional Pap smears, or monolayers with or without HPV testing) and by the reference method: colposcopy followed, in cases with abnormalities, by cervical biopsy. Efficacy or performance of the methods will be compared on the basis of sensitivity. Cost comparisons and cost-effectiveness modeling will be based on the costs associated with methods themselves and also the costs of “false positives.” This will require specific collection of data concerning the costs of the three methods, as these costs have not previously been accurately documented. Patient recruiting and data collection started in September 1999 and will be complete in June 2000. The first results are expected to be available in spring 2001. Diagn. Cytopathol. 24:412–420, 2001. © 2001 Wiley-Liss, Inc.
    Diagnostic Cytopathology 05/2001; 24(6):412 - 420. · 1.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND The aim of this study was to evaluate the rate of squamous intraepithelial lesions (SIL) in women with reactive cellular change (RCC) cervical smears and compare the results with a control group with within normal limit (WNL) smears.METHODS The study group was comprised of 1000 women with RCC and a control group of 1000 women with WNL cervical smears diagnosed over an 8-month period. Results of the first follow-up (FU) smears were evaluated and compared between the two groups. FU smears with a diagnosis of SIL were reviewed along with the original RCC or WNL smears.RESULTSSix hundred and thirteen women from the RCC group and 640 from the WNL group had FU smears. The mean time to FU was 11.0 and 13.8 months, respectively. FU revealed SIL in 24 of 613 smears in the RCC group (20 low grade [L] SIL and 4 high grade [H] SIL), (3.9%) and in 10 of 640 smears in the WNL group (10 LSIL and 0 HSIL) (1.6%). Fisher's exact test (two-tailed) showed statistical significance (P = 0.014). On retrospective review of the FU smears diagnosed as SIL and their corresponding original RCC or WNL smears, four RCC smears were upgraded to atypical squamous cells of undetermined significance (ASCUS). The remaining diagnoses remained unchanged.CONCLUSIONS Women with RCC are more likely to have SIL on a FU smear compared with women with WNL smears (3.9% vs. 1.6%). It is important to emphasize that in the authors' laboratory, the rate of SIL in women with ASCUS is much higher (24%). Awareness of these rates combined with the clinical history may help clinicians determine whether women with RCC require closer FU. [See editorial counterpoint on pages 137-8, this issue.] Cancer (Cancer Cytopathol) 1997; 81:144-7. © 1997 American Cancer Society.
    Cancer 11/2000; 81(3):144 - 147. · 5.20 Impact Factor